Citius Pharmaceuticals Files 8-K
Ticker: CTXR · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1506251
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-update
TL;DR
Citius Pharma filed an 8-K on Sept 5th - check for updates.
AI Summary
Citius Pharmaceuticals, Inc. filed an 8-K on September 5, 2024, reporting other events and financial statements. The company, incorporated in Nevada, has its principal executive offices in Cranford, NJ.
Why It Matters
This filing indicates a routine update or disclosure from Citius Pharmaceuticals, Inc. to the SEC, which may contain important information for investors.
Risk Assessment
Risk Level: low — This is a standard SEC filing (8-K) that typically reports material events or financial updates, not inherently indicating high risk.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- Cranford, NJ (location) — Principal executive offices
- September 5, 2024 (date) — Date of earliest event reported
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' reported, only that this item is included in the filing.
What is the nature of the 'Financial Statements and Exhibits' being filed?
The filing indicates that financial statements and exhibits are part of this 8-K, but their specific content is not detailed in the provided text.
When was Citius Pharmaceuticals, Inc. incorporated, and in which state?
Citius Pharmaceuticals, Inc. was incorporated in Nevada.
What is the address of Citius Pharmaceuticals, Inc.'s principal executive offices?
The principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
What is the Commission File Number for Citius Pharmaceuticals, Inc.?
The Commission File Number for Citius Pharmaceuticals, Inc. is 001-38174.
Filing Stats: 424 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-09-05 16:15:10
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital M
Filing Documents
- ea0213639-8k_citius.htm (8-K) — 27KB
- ea021363901ex99-1_citius.htm (EX-99.1) — 35KB
- ex99-1_001.jpg (GRAPHIC) — 12KB
- 0001213900-24-076108.txt ( ) — 259KB
- ctxr-20240905.xsd (EX-101.SCH) — 3KB
- ctxr-20240905_lab.xml (EX-101.LAB) — 33KB
- ctxr-20240905_pre.xml (EX-101.PRE) — 22KB
- ea0213639-8k_citius_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 5, 2024, Citius Pharmaceuticals, Inc. issued a press release to announce that LYMPHIR has been added to the NCCN Clinical Practice Guidelines in Oncology. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibit is filed herewith: Exhibit No. Description 99.1 Press Release dated September 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: September 5, 2024 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2